Theravance Biopharma Balance Sheet Health
Financial Health criteria checks 4/6
Theravance Biopharma has a total shareholder equity of $213.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $382.0M and $169.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$102.43m |
Equity | US$213.00m |
Total liabilities | US$169.00m |
Total assets | US$382.00m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0TB's short term assets ($133.5M) exceed its short term liabilities ($24.8M).
Long Term Liabilities: 0TB's short term assets ($133.5M) do not cover its long term liabilities ($144.2M).
Debt to Equity History and Analysis
Debt Level: 0TB is debt free.
Reducing Debt: 0TB currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0TB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0TB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.